Related Experiment Video

Updated: Jun 2, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

[Coronary stent thrombosis: what's new in 2011?]

M Oberhänsli1, S Puricel, M Togni

  • 1Cardiology, University Fribourg, Schweiz.

Herz
|April 21, 2011
PubMed

Insights

Stent thrombosis (ST), a complication of percutaneous coronary interventions (PCI), has high mortality. Optimizing dual antiplatelet therapy and using newer agents can reduce ST risk.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology

Context:

  • Stent thrombosis (ST) is a critical complication following percutaneous coronary interventions (PCI), associated with significant mortality.
  • Both bare metal stents (BMS) and drug-eluting stents (DES) exhibit comparable rates of early and late ST.
  • Very late ST is a distinct concern with first-generation DES, linked to healing issues and hypersensitivity.

Purpose:

  • To review the incidence, predictors, and prevention strategies for stent thrombosis.
  • To highlight the role of dual antiplatelet therapy (DAPT) and emerging pharmacologic agents in mitigating ST risk.

Summary:

  • ST occurs early, late, and very late after PCI, with rates varying by stent type and time post-procedure.
  • Key predictors include inadequate platelet inhibition, procedural complications (e.g., stent underexpansion), and patient factors (e.g., diabetes, renal failure).
  • Premature DAPT cessation and clopidogrel resistance are significant ST risk factors, while newer agents like prasugrel and ticagrelor offer improved outcomes.

Impact:

  • Understanding ST predictors and risk factors is crucial for optimizing patient management after PCI.
  • The introduction of novel antiplatelet agents promises to further reduce the incidence of ST.
  • Improved prevention strategies can lead to better long-term outcomes for patients undergoing coronary interventions.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...